Recurrent Diseases in the Transplant

Simin Goral MD
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania
Recurrent Disease after Kidney Transplantation—It Is Time to Unite to Address This Problem!

A. J. Matas*

University of Minnesota, Minneapolis, Minnesota, USA
*Corresponding author: Arthur J. Matas, matas001@umn.edu

rates. Late graft loss has become one of the leading causes of end-stage renal disease (ESRD).

There are multiple causes of late kidney allograft loss. Each must be addressed if we are to improve outcomes. Most attention is paid to the two commonest causes—death
Case #1

- 21-year-old male, was on hemodialysis since September 2005
- History of nephrotic range proteinuria and hematuria at the age of 3
- Kidney biopsy (native): FSGS, treated with high dose steroids and Cytoxan
- Living-related kidney transplant 3/14/2006, Scr down to 1/7 mg/dl
- 3/27/06: On 6 mg TID of Prograf, Scr 2.0 mg/dl, urine protein/creat ratio 2.2, platelets 120,000
- Transplant biopsy done
Case #1

- Kidney biopsy:
  - Small numbers of glomerular capillary platelet thrombi consistent with thrombotic microangiopathy
  - Acute tubular necrosis
  - No evidence for rejection
  - Extensive visceral epithelial foot process effacement, most likely early recurrence of a sclerosing glomerulopathy
Case #1

• Clinical course:
  • Prograf dose decreased to a level around 4 (TAC 4 mg bid), also on MMF, prednisone
  • Plasmapheresis x 10 treatment
  • Urine protein/creat ratio is down to 0.2, platelets > 150,000
  • Repeat kidney biopsy 6/1/06: no rejection, no TMA, early FSGS
  • Last clinic visit (17 months after surgery): on valsartan, lisinopril and spironolactone, Scr 1.7 mg/dl, urine prot/creat ratio: 4.5
Case #2

- 37 yo male, biopsy-proven FSGS, treated with high dose steroids, Cytoxan, azathioprine, and cyclosporine
- Started PD in January 2002
- Received a CAD kidney in August 2004-never worked
- Transplant nephrectomy in October 2005
- Second CAD kidney transplant on 11/30/2005
Case #2

- 1/30/06: urine protein/creat ratio: 5.8
- Kidney biopsy 2/1/2006:
  - Banff "Borderline changes", suspicious for early acute cellular rejection and mild mesangial proliferative glomerulopathy with significant effacement of the visceral epithelial foot processes as a background lesion for early FSGS
Case #2

- Clinical course:
  - Steroids x3 (500 mg, IV)
  - Plasmapheresis x10
  - Initial decrease in proteinuria to 1.7 g/d, then increased to 7.5 g/d
  - Patient does not want to continue PE
  - On Valsartan and ramipril, Scr 1.6-1.8 mg/dl, protein/creatinine ratio: 11, kidney function worsened and started dialysis 14 months after surgery
Case #3

- 21 year old African American woman
- ESRD due to biopsy-proven lupus nephritis (class V) and h/o anti-cardiolipin antibody syndrome
- Living-unrelated kidney transplant from her husband
- ATS induction, on Neoral + Cellcept + Prednisone for maintenance
Case #3

- Microscopic hematuria, proteinuria (2.7 g/day) and worsening kidney function (Scr 2.5 mg/d)
- Kidney biopsy: Focal proliferative GN with crescents and immune complexes (WHO class III, SLE)
- Solu-Medrol pulses (250 mg x 3), prednisone 60 mg/d
Case # 3

- Severe herpes esophagitis and CMV infection
- ACE inhibitor, good blood pressure control, on 1000 mg twice a day Cellcept
- Returned to dialysis 8 years after transplantation
Recurrent Disease: Diagnosis

Biopsy proven GN on native kidney

Posttransplant proteinuria or hematuria or elevated creatinine

Biopsy proven GN on kidney transplant
Risk of Graft Loss From Recurrent GN

- 1505 patients with biopsy-proven GN from Australia (1988-1997)
- The incidence of allograft loss due to recurrence at 10 years was 8.4% and increased overtime
- Most frequent causes of allograft loss at 10 years: 1. Chronic rejection, 2. Death with a functioning graft, 3. Recurrence
- Recurrence is more frequent than acute rejection as a cause of allograft loss during first 10 years after transplant

Briganti EM, et al NEJM 2002
Recurrent GN in the Transplant

- The prevalence: 1.9%-31% in different series
- Higher prevalence in patients with ESRD due to biopsy-proven GN
- Higher recurrence: younger age, male gender, re-transplants, use of antilymphocytic serum for induction
- 1-8.4% of all graft failures are due to recurrent disease
- **Recurrence is an important cause of allograft loss for those with ESRD due to GN**
Causes of Graft Loss
(Living Kidney Transplantation from HLA-identical Sibling Donors)


<table>
<thead>
<tr>
<th>Table 2</th>
<th>Cause of graft loss, by time post-transplant</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt;1 years</td>
</tr>
<tr>
<td></td>
<td>Non-identical</td>
</tr>
<tr>
<td>Acute rejection</td>
<td>5 (41.7%)</td>
</tr>
<tr>
<td>CAN with/without CR</td>
<td>2 (16.7%)</td>
</tr>
<tr>
<td>CNI nephrotoxicity</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Recurrence of original disease</td>
<td>1 (8.3%)</td>
</tr>
<tr>
<td>Death with functioning graft</td>
<td>2 (16.7%)</td>
</tr>
<tr>
<td>Discontinuation of immunosuppressant</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Non-compliance</td>
<td>1 (8.3%)</td>
</tr>
<tr>
<td>Others</td>
<td>1 (8.3%)</td>
</tr>
<tr>
<td>P</td>
<td>0.2002</td>
</tr>
</tbody>
</table>
Causes of Graft Loss

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Cause of recurrent disease in graft loss recipients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Non-identical</td>
</tr>
<tr>
<td>IgA nephropathy</td>
<td>7 (63.6%)</td>
</tr>
<tr>
<td>FGS</td>
<td>3 (27.3%)</td>
</tr>
<tr>
<td>MPGN</td>
<td>1 (9.1%)</td>
</tr>
</tbody>
</table>

FGS, focal glomerulosclerosis; IgA, immunoglobulin A; MPGN, membranoproliferative glomerulonephritis.

Recurrent GN in the Transplant

- Renal Allograft Disease Registry (RADR):
  - 167 cases (3.4%) of recurrent and de novo diseases in 4913 renal transplants from 6 U.S. centers (1987-1996)
  - More men and a higher number of re-transplants in this group
  - No difference according to the transplant type (LRD vs CAD)
  - More graft failures (55% vs 25%, p<0.001) and shorter half-life in the recurrent disease group

Hariharan S et al, Transplantation 1999
Recurrent GN in the Transplant (RADR Report)

- **RADR findings:**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Recurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td>FSGS (n= 57)</td>
<td>53%</td>
</tr>
<tr>
<td>IgA nephropathy (n=22)</td>
<td>50%</td>
</tr>
<tr>
<td>MPGN (n=18)</td>
<td>61%</td>
</tr>
<tr>
<td>Membranous GN (n=16)</td>
<td>50%</td>
</tr>
<tr>
<td>Diabetic nephropathy (n=19)</td>
<td>100%</td>
</tr>
<tr>
<td>HUS/TTP (n=8)</td>
<td>100%</td>
</tr>
</tbody>
</table>
Risk Factors for Allograft Failure

- Cadaveric transplants
- Prolonged cold ischemia time (>20 hours)
- Elevated panel reactive antibody (>20%)
- The relative risk for graft failure because of recurrent and de novo disease was 1.9
- The highest RR for graft failure: HUS/TTP (5.36), MPGN (2.37) and FSGS (2.25)

Hariharan S et al, Transplantation 1999
A Prospective Study from RADR

- Recipients transplanted from 1998-2002
- 90/3216 (2.7%) with recurrent or de novo disease
- 853/3216 (26%) with prior native kidney biopsy, 36/853 (4.2%) developed recurrence
- FSGS (7.4%), SLE (7.2%), MPGN (6.8%), and IgA (4.2%)

Hussain SA et al, abstract #323, AST 2003
## Recurrent Disease After Kidney Tx: Little Progress in 2 Decades

**Table 1 - Primary transplants**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>FSGS - adult</td>
<td>n - % 10-yr recurrence</td>
<td>n - % 10-yr recurrence</td>
<td>.7</td>
<td>39 - 4%</td>
<td>74 - 17%</td>
<td>.08</td>
</tr>
<tr>
<td>FSGS - pedis</td>
<td>16 - 14%</td>
<td>12 - 25%</td>
<td>.3</td>
<td>16 - 14%</td>
<td>12 - 18%</td>
<td>.8</td>
</tr>
<tr>
<td>MPGN</td>
<td>46 - 6%</td>
<td>38 - 31%</td>
<td>.02</td>
<td>46 - 5%</td>
<td>38 - 13%</td>
<td>.3</td>
</tr>
<tr>
<td>HUS</td>
<td>12 - 47%</td>
<td>11 - 0%</td>
<td>.08</td>
<td>12 - 47%</td>
<td>11 - 0%</td>
<td>.07</td>
</tr>
<tr>
<td>IgA</td>
<td>45 - 0%</td>
<td>96 - 6%</td>
<td>.07</td>
<td>45 - 0%</td>
<td>96 - 2%</td>
<td>.35</td>
</tr>
<tr>
<td>GN</td>
<td>10 - 15%</td>
<td>17 - 6%</td>
<td>.9</td>
<td>10 - 0%</td>
<td>17 - 0%</td>
<td>1</td>
</tr>
<tr>
<td>Lupus</td>
<td>30 - 8%</td>
<td>36 - 0%</td>
<td>.2</td>
<td>30 - 5%</td>
<td>36 - 0%</td>
<td>.4</td>
</tr>
<tr>
<td>Wegener’s</td>
<td>5 - 0%</td>
<td>7 - 33%</td>
<td>.1</td>
<td>5 - 0%</td>
<td>7 - 33%</td>
<td>.1</td>
</tr>
</tbody>
</table>

GL = graft loss

Sturdevant, M et al. WTC 2006, abstract#298
# Recurrence After Transplantation

<table>
<thead>
<tr>
<th>Disease</th>
<th>Recurrence Rate</th>
<th>Graft Loss due to Recurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td>FSGS</td>
<td>20-50%</td>
<td>40-50%</td>
</tr>
<tr>
<td>Anti-GBM disease</td>
<td>10-25%</td>
<td>unusual</td>
</tr>
<tr>
<td>Membranous GN</td>
<td>10-20%</td>
<td>50%</td>
</tr>
<tr>
<td>IgA nephropathy</td>
<td>40-50%</td>
<td>6-33%</td>
</tr>
<tr>
<td>Type I MPGN</td>
<td>20-30%</td>
<td>20-40%</td>
</tr>
<tr>
<td>Type II MPGN</td>
<td>80-90%</td>
<td>10-20%</td>
</tr>
</tbody>
</table>
# Recurrence After Transplantation

<table>
<thead>
<tr>
<th>Condition</th>
<th>Recurrence Rate</th>
<th>Graft Loss due to Recurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Henoch-Schönlein</td>
<td>15-35%</td>
<td>10-20%</td>
</tr>
<tr>
<td>Lupus nephritis</td>
<td>1-25%</td>
<td>Rare</td>
</tr>
<tr>
<td>HUS</td>
<td>10-25%</td>
<td>50%</td>
</tr>
<tr>
<td>Diabetic nephropathy</td>
<td>100%</td>
<td>5%</td>
</tr>
<tr>
<td>Amyloidosis</td>
<td>2-33%</td>
<td>20%</td>
</tr>
<tr>
<td>Wegener’s</td>
<td>15-50%</td>
<td>10%</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>Clinically relevant (^1) recurrent risk (^2)</td>
<td>Risk of graft loss due to recurrence 5–10 years post-transplant (^2)</td>
</tr>
<tr>
<td>------------------------------------</td>
<td>-----------------------------------------------</td>
<td>---------------------------------------------------------------------</td>
</tr>
<tr>
<td>IgAN</td>
<td>13–46%</td>
<td>2–16%</td>
</tr>
<tr>
<td>FSGS</td>
<td>20–50%</td>
<td>13–20%</td>
</tr>
<tr>
<td>MPGN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type I</td>
<td>20–25%</td>
<td>~15%</td>
</tr>
<tr>
<td>Type II</td>
<td>80–100%</td>
<td>15–30%</td>
</tr>
<tr>
<td>Membranous nephropathy</td>
<td>10–30%</td>
<td>10–15%</td>
</tr>
<tr>
<td>ANCA-associated glomerulonephritis</td>
<td>~17%</td>
<td>6–8%</td>
</tr>
<tr>
<td>SLE</td>
<td>2–9%</td>
<td>2–4%</td>
</tr>
<tr>
<td>Anti-GBM</td>
<td>Rare</td>
<td>Rare</td>
</tr>
</tbody>
</table>

*Choy BY, et al. Am J Transplant 2006*
Recurrent FSGS

• **Recurrence rate**: 20-50% (difficult because of the focal nature of the distribution of lesions and possible sampling error)

• **Graft loss**: in ~50% of recurrent cases
Factors Contributing to Recurrence of FSGS

- Early onset (<15 years) of nephrotic syndrome
- Rapidly progressive FSGS in the native kidneys
- Race (more in African Americans), African-American kidney in a white recipient
- Diffuse mesangial proliferation on original kidney biopsy
- History of recurrence in a previous transplant
Factors Contributing to Recurrence of FSGS

- Circulating protein that alters glomerular capillary permeability?  
  (Savin V, et al)
- Induction therapy with ALS (more with ATGAM)  
  (Raafat R et al, Pediatr Nephrol 2000)
- Increased intra-graft NF-kappaB expression and intra-graft angiotensinogen gene expression (potential marker for recurrence?)  
  (Schachter AD et al, Transplantation 2000)
- Patients with active FSGS or with posttx recurrence had oxidized plasma albumin-free radical involvement in FSGS  
Recurrent FSGS

- NAPRTCS database, age 13-17 year
- Clinical: malignant, diagnosis to dialysis is usually <3 years, nephrotic range proteinuria, ~75-80 % recurrence in the second graft
- Waiting 1-2 years between transplants
- Living-related vs cadaveric renal transplantation (controversial): Graft loss due to recurrent disease, no difference between LD (17%) or CAD (13.8%) grafts in NAPRTCS data

Baum MA et al, Pediatr Transplantation 2002
Recurrent FSGS

- 2,414 patients in 19,259 adult primary renal transplant recipients
- Death-censored graft survival rates among FSGS patients

Cibrik DM, Kaplan B, Campbell DA, Meier Kriesche H, AJT 2003
Recurrent FSGS

• Superior death-censored graft survival for FSGS patients who received a zero mismatch LD kidney vs HLA-mismatched CAD kidney

• Similar results in FSGS patients vs patients with other GN (zero mismatch LD kidney)

Cibrik DM, Kaplan B, Campbell DA, Meier Kriesche H, AJT 2003
Five-year Death-censored Renal Allograft Survival (FSGS Vs Other GN)
Five-year Death-censored Renal Allograft Survival (FSGS)
Recurrent FSGS

- Limitations: retrospective, diagnosis of FSGS (biopsy-proven?), secondary causes of FSGS, incidence of recurrence
- Zero-mismatch LR transplant is NOT a risk factor for graft loss in FSGS, associated with significantly better death-censored renal allograft survival

Cibrik DM, Kaplan B, Campbell DA, Meier Kriesche H, AJT 2003
Treatment for Recurrent FSGS

• 100 consecutive pediatric renal transplants
• 20 patients with FSGS, 8/20 (40%) with recurrence within 1 month of transplantation
• Plasmapheresis (mean: 24±17, range: 8-51 treatments to achieve a remission) in 5/6 pts
• One plasma volume was replaced with 5% albumin, 4 times per week then tapered when proteinuria decreased

Greenstein SM et al, Pediatr Nephrol 2000
Treatment for Recurrent FSGS

- No prospective randomized studies
- Plasmapheresis ± dipyridamole (pre-or post transplant), ~50% relapse after stopping plasmapheresis, nonresponders: sclerosis on biopsy, less effective in adults
- Pre-transplant plasmapheresis in children (retrospective data)
- Plasma protein adsorption
- High-dose cyclosporine, cyclophosphamide
- ACE inhibitors, NSAIDs, rapamycin use (Odama-Nwogu U et al, abstract#55, AST 2003)
Resolution of Recurrent Focal Segmental Glomerulosclerosis Proteinuria after Rituximab Treatment

Pescovitz MD, Book BK, Sidner RA
Figure 1. Serum Levels of Creatinine and Albumin and the Urinary Protein:Creatinine Ratio in the Index Patient after the Initiation of Treatment.
FSGS and Transplantation

- There are not yet sufficient data for or against the use of prophylactic plasma exchange or other measure to prevent recurrent FSGS
- Native nephrectomy is not useful as a prevention
FSGS and Transplantation

- FSGS can recur in minutes after tx
- Massive proteinuria → massive edema
- Posttx acute renal failure mimicking delayed graft function (DGF)
- Allograft biopsy-needed for diagnosis
FSGS and Transplantation

- Candidates with FSGS should be warned about the 30-50% risk of recurrence.
- The risk of recurrence should not preclude transplantation.
- Cadaveric versus LRD transplant (ethical issues).
- Should prior history of graft loss from recurrent FSGS be considered a relative contraindication to living donor transplantation (recurrence up to 80%)?
Recurrent IgA Nephropathy

- Recurrence rate: 40-60%
- Risk factors:
  - Younger age, HLA B35 and DR4 antigen
  - LRTx, high titers of serum IgA RF
  - Short interval between onset and ERSD
  - Glomerular crescents on original biopsy
  - Better donor/recipient HLA matching?
  - Greater number of rejections, previous h/o recurrence
  - IL-10 gene G-1082A polymorphism-worse outcome

(Ivens K, et al ATC 2007, abstract#350)
Recurrent IgA Nephropathy

- **Graft loss**: 6-35%
- **Clinical**: microscopic hematuria ± proteinuria, worsening renal function, usually late recurrence, progression to ESRD is very slow
- **Treatment**: tonsillectomy (case reports from Japan), mycophenolate mofetil, high-dose fish oil, ACE inhibitors *(WTC 2006 abstract#1790)*
Recurrent Membranous Nephropathy (MN)

- Recurrence rate: 5%-42%
- Most cases are idiopathic, can be secondary to infectious agents (hepatitis B and C) or to SLE
- De novo MN is more frequent than recurrent MN
- Surveillance biopsies: 42% of patients developed histologic evidence of recurrence by 5 years, in most cases by 1-year post-tx. Minor clinical manifestations at diagnosis-Mayo Clinic exp.

Dabade TS, et al ATC 2007, abstract#351
Recurrent Membranous Nephropathy

- **Graft loss**: rare-30%
- **Risk factors**: male gender, rejection, HLA-identical living-related transplants
- **Clinical**: nephrotic range proteinuria, venous thrombosis of the allograft
- **Treatment**: Protein A immunoadsorption, pulse methylprednisolone and high-dose alternate day steroids, ACE inhibitors and MMF, *early use of rituximab-Mayo Clinic exp*

  Cosio FG, et al ATC 2007, abstract#352
Recurrent MPGN

- **Recurrence rate**: 20-30% in type I, 80-100% in type II
- **Graft loss**: 40% in type I, 10-20% in type II
- **Risk factors**: male gender, rapid progression to ESRD, massive proteinuria, identical LRD, recurrence on the first graft, HLA haplotype B8DR3 (*Andresdottir et al, Transplantation 1997*)
- *May mimic chronic allograft nephropathy*
Recurrent MPGN

- **Clinical**: in secondary MPGN positive serology for hepatitis C ± cryoglobulinemia, low complement levels and rheumatoid factor, hematuria or proteinuria

- **Treatment**: Aspirin, steroids, cyclophosphamide, plasmapheresis is not useful
Rates of Graft Failure by Cause in the First 5 Years Post-Tx (per 100 patient-years)

<table>
<thead>
<tr>
<th>Cause of Kidney Disease</th>
<th>Recurrence</th>
<th>Death</th>
<th>Other</th>
<th>Recurrence</th>
<th>Death</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>MPGN</td>
<td>0.82</td>
<td>1.59</td>
<td>5.79</td>
<td>1.73</td>
<td>1.40</td>
<td>3.79</td>
</tr>
<tr>
<td>Other GN</td>
<td>0.43</td>
<td>1.78</td>
<td>4.99</td>
<td>0.47</td>
<td>1.64</td>
<td>3.43</td>
</tr>
<tr>
<td>Cystic Disease</td>
<td>0.05</td>
<td>2.33</td>
<td>2.64</td>
<td>0.09</td>
<td>1.68</td>
<td>1.72</td>
</tr>
<tr>
<td>Diabetes</td>
<td>0.14</td>
<td>4.85</td>
<td>3.90</td>
<td>0.14</td>
<td>4.73</td>
<td>2.77</td>
</tr>
<tr>
<td>Hypertension</td>
<td>0.28</td>
<td>3.41</td>
<td>6.35</td>
<td>0.29</td>
<td>2.99</td>
<td>4.65</td>
</tr>
<tr>
<td>Other</td>
<td>0.16</td>
<td>2.40</td>
<td>3.60</td>
<td>0.19</td>
<td>1.93</td>
<td>2.70</td>
</tr>
</tbody>
</table>

- USRDS database, total n=140,109, MPGN=1,574
- the rate of graft failure due to recurrent MPGN was more than 2-fold greater after TX in 1995-03 compared to TX in 1988-94

Kasiske, B, et al, WTC 2006, abstract#1765
Recurrent Lupus Nephritis (RLN)

- **Recurrence rate**: <10% in the literature
- **Graft loss**: reported rare
- **Risk factors**: active disease at the time of transplant (controversial), longer duration on dialysis before transplant (>25 weeks)
- **Clinical**: proteinuria, hematuria, and/or elevated serum creatinine, rarely extrarenal manifestations such as arthralgia, fever, skin rash and leukopenia
RLN-Vanderbilt Experience

- 50 SLE patients with at least 3 months of follow-up
- Induction with antithymocyte ab: 39 patients
- Immuno: AZA+pred (n=11), CsA (n=39), only 9 patients on CsA+MMF+pred
- Mean follow-up: 6.8±4.9 years; biopsy in 31 patients (62%)
- Recurrence rate: 52% of the patients biopsied, 30% of total patients
- One graft loss due to recurrent SLE

Goral S et al, Transplantation 2003
RLN-Vanderbilt Experience

- Patient survival: 96% at 1 year, 82% at 5 years
- Graft survival: 87% at 1 year, 60% at 5 years
- No difference in graft survival between group 1 (RLN) and group 2 (no RLN)
- Graft survival was worse in patients who were biopsied compared to patients who never had any biopsies
- Worse outcome: one or more acute rejection and presence of chronic rejection

Goral S et al, Transplantation 2003
Graft Failure Rates by Cause in the First 5 Years Post-Tx (per 100 patient-years)

<table>
<thead>
<tr>
<th>Cause of Kidney Disease</th>
<th>Recurrence</th>
<th>Death</th>
<th>Other</th>
<th>Recurrence</th>
<th>Death</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLE</td>
<td>0.39</td>
<td>1.59</td>
<td>6.27</td>
<td>0.39</td>
<td>1.59</td>
<td>3.93</td>
</tr>
<tr>
<td>Other GN</td>
<td>0.45</td>
<td>1.79</td>
<td>4.89</td>
<td>0.54</td>
<td>1.63</td>
<td>3.38</td>
</tr>
<tr>
<td>Cystic Disease</td>
<td>0.05</td>
<td>2.33</td>
<td>2.64</td>
<td>0.09</td>
<td>1.68</td>
<td>1.72</td>
</tr>
<tr>
<td>Diabetes</td>
<td>0.14</td>
<td>4.85</td>
<td>3.90</td>
<td>0.14</td>
<td>4.73</td>
<td>2.77</td>
</tr>
<tr>
<td>Hypertension</td>
<td>0.28</td>
<td>3.41</td>
<td>6.35</td>
<td>0.29</td>
<td>2.99</td>
<td>4.65</td>
</tr>
<tr>
<td>Other</td>
<td>0.16</td>
<td>2.40</td>
<td>3.60</td>
<td>0.19</td>
<td>1.93</td>
<td>2.70</td>
</tr>
</tbody>
</table>

(USRDS database, total n=140,109, SLE=4,832)

Kasiske, B et al, WTC 2006, abstract#1764
Recurrent Lupus Nephritis

- It is difficult to predict when RLN will occur after transplantation
- RLN can occur as early as 6 days after transplantation
- Surveillance biopsies might be helpful
- RLN may or may not have the same pattern as the original disease
Recurrent Lupus Nephritis

- **Treatment**: No definite treatment options (MMF), the impact of new immunosuppressive agents?
- **Transplant kidney biopsy specimens from patients with history of ESRD due to SLE should be evaluated by both IF and EM in addition to LM** (8 of 15 patients with RLN had mesangial LN)
Recurrent Diabetic Nephropathy

- **Recurrence rate**: up to 100%
  - *Recurrence of GBM thickening and mesangial expansion 2 years beyond transplantation*
- Reported as early as 2.5 years after transplant
- **Graft loss**: <5% in short-term, ?predictor of graft loss
- **Risk factors**: suboptimal glycemic control
  - (histological lesions are not observed in kidney-pancreas recipients)
- **Treatment**: No studies
Recurrent Diabetic Nephropathy

• 58 patients; 74% had pretx-DM and 26% had posttx DM
• Biopsy proven diabetic nephropathy (done for clinical indications): 70% recurrent DN and 30% de novo DN
• De novo diabetic nephropathy at least as frequent as recurrent DN

Bhalla V, Transplantation 2003
Recurrence of ANCA-Associated Vasculitis

- 35 patients with ANCA-associated vasculitis: microscopic polyangiitis (20 patients) and Wegener’s granulomatosis (15 patients)
- The median time from diagnosis to transplantation: 25 months
- All patients in clinical remission
- 15 patients ANCA-positive at time of the transplant with 13 preemptive transplants
- Mean follow-up: 4.4±2.5 years

Recurrence of ANCA-Associated Vasculitis

- Antibody induction, steroids, mycophenolate mofetil, and tacrolimus
- Biopsy-proven AR in 6 recipients (23%) and BK nephropathy in 3 recipients (6%)
- Overall and death-censored graft survivals were 94 and 100%, respectively, 5 years post-transplantation
- Relapse of vasculitis in three of 35 patients (8.6% all nonrenal, reported up to 20% relapse rate in the literature-50% renal involvement)

Recurrent Hemolytic Uremic Syndrome

- Recurrence rate: 13-50%
- Graft loss: 10-50%
- Risk factors: older age at onset of HUS, shorter interval between HUS onset and transplantation, LRDs, the use of calcineurin inhibitors (a meta-analysis, Ducloux D et al, Transplantation 1998)
- Clinical: microangiopathic hemolytic anemia, thrombocytopenia, worsening renal function
- *Sporadic HUS generally does not recur
Potential Problems for Identifying Recurrent GN in the Transplant

• No unified approach for patients with urinary abnormalities and increased serum creatinine after transplantation (histological vs clinical diagnosis)
• Primary disease is unknown for many patients
• Transplant biopsy is not routinely submitted for IF and EM examination
Potential Problems for Identifying Recurrent GN in the Transplant

• Interpretation of the biopsy: DIFFICULT, *de novo* vs recurrent-MPGN vs chronic rejection vs changes already present in the grafted kidney
• Most of the studies are small and retrospective with variable follow-up periods (mostly short-term, inconsistent f/u)
• *No randomized, prospective studies for different treatment regimens (only case reports: MMF promising)*
Recommendations

• The selection of recipients and donors should be no different for patients with GN from other candidates for kidney transplantation

• Potential recipients and donors should, however, be informed of the risk of recurrence
Post-Transplant GN - Recurrent or De Novo

- The best predictor factors that correlated with graft survival were:
  - Proteinuria <3.5 g [relative risk (RR) = 0.24, p = 0.017]
  - Serum creatinine below 2.0 mg/dL (RR = 0.06, p = 0.016) at the time of biopsy
  - The use of angiotensin-converting enzyme inhibitors (ACEI) (RR = 0.12, p = 0.005). The use of ACEI markedly improved one-yr graft survival rates (92% vs. 47%, p < 0.001)

Challenges/Recommendations

• Awareness of recurrence
• Why do certain primary diseases affecting the native kidney recur?
• Obtain an exact diagnosis of primary disease
• Clarify the causes of prior graft loss
• Careful urinalysis in renal transplant recipients
• Early histological evaluation-low threshold for biopsy
• Prospective studies for specific treatments in individual diseases
Future Studies

• Prospective trials/registries:
  • Recurrence rate
  • Living donor vs. cadaver transplantation
  • Various immunosuppressive protocols
  • History of prior dialysis
  • The recurrence rate for degree of HLA mismatch
  • Identify risk factors for recurrence
Future Studies

• Selective prospective, interventional studies to prevent, delay recurrence and modify progression for individual diseases
  • Prevention and treatment of FSGS with plasmapheresis
  • Prevention of SLE and IgA nephritis with mycophenolate mofetil in renal transplant recipients
  • Role of sirolimus in *de novo* HUS/TTP
  • Management of HUS/TTP with plasmapheresis
Oxalosis

• Recurrence rate: early experience very high recurrence with allograft loss, now better results with:
  1. Early transplantation (GFR 20 ml/min)
  2. Aggressive preoperative dialysis
  3. High urine flow after surgery
  4. Simultaneous/sequential liver and kidney transplants

• Liver transplant followed by a kidney transplant (56): superior death-censored graft survival compared with patients who received a cadaveric or living-donor kidney transplant alone (134) (Cibrik DM et al, Transplantation 2002)
Amyloidosis

- Living-related kidney transplantation in 23 patients with ESRD due to amyloidosis, 47 controls
- Familial Mediterranean fever (FMF) in 16 patients and primary (idiopathic) in 7 transplant recipients
- Five- and 10-year actuarial graft survival rates were similar in both groups (79.35% vs 84.04% and 65.92% vs 56.61%, respectively)
- Five- and 10-year actuarial patient survival rates also were similar (80% vs 94% and 68% vs 87%, respectively)

Amyloidosis

- Only one recurrence 10 years after transplantation (4.3%)
- Maintenance colchicine
- More GI problems and low blood pressure


- Twenty of 30 patients (67%), biopsy confirmed recurrence after transplant (mostly well-matched LRDs)

Ozdemir B et al, Tissue Antigens 2002
Vasculitis or Anti-GBM Disease

• 43 patients: Wegener's granulomatosis (n = 8), microscopic polyangiitis (n = 7), renal limited vasculitis (n = 18) and anti-GBM disease (n = 10)
• Average follow-up: 62+-57 months
• No graft was lost due to recurrence of the underlying disease
• Patient and graft survival at 5 years after transplantation were 77% and 60%
• More malignancies

Deegens JK et al, Clin Nephrol 2003
Recurrent Fibrillary GN

- Recurrence rate: up to 50%
- 14 patients reported in the literature
- Clinical: benign course, prolonged graft survival is possible
- No evidence of systemic disease
- No definite treatment modality
Risk of Recurrent Disease

1. Should a kidney from a live donor be used if the recipient has an increased risk of recurrent disease?

2. Is there a greater chance that the recipient will lose the allograft from recurrent disease if a relative donor is used?

3. Will the same disease recipient has some day cause renal failure in the donor?
Kidney Transplantation In Patients With Lupus Nephritis Utilizing Modern Immunosuppression

- 29 patients with lupus nephritis (26 females and 3 males; 13 AA, 13 W, 2 Asians and 1 Hispanic)
- Transplanted between 1/2000 and 6/2005
- Treated uniformly with antibody induction and the combination of tacrolimus, MMF and prednisone
- Three patients (11%) were treated for acute rejection

Kidney Transplantation In Patients With Lupus Nephritis Utilizing Modern Immunosuppression

- Of 13 patients biopsied, only 2 had LM, IF and EM done, only one had recurrent lupus nephritis (5 years after the transplant)
- One-year graft and patient survival rates were 96% and 96%, respectively
- Three-year graft and patient survival rates were 88% and 88%, respectively
- Could this be due to uniform use of MMF in combination with tacrolimus in this population?
- The impact of this immunosuppressive combination on long-term survival and recurrence remains to be seen